Cargando…

Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation

BACKGROUND: Myeloablative (MAC) and reduced-intensity conditioning (RIC) are established approaches for allogeneic stem cell transplantation (SCT) in acute myeloid leukemia (AML). Most deaths after MAC occur within the first 2 years after SCT, while patients surviving leukemia-free for 2 years can e...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimoni, Avichai, Labopin, Myriam, Savani, Bipin, Volin, Liisa, Ehninger, Gerhard, Kuball, Jurgen, Bunjes, Donald, Schaap, Nicolaas, Vigouroux, Stephane, Bacigalupo, Andrea, Veelken, Hendrik, Sierra, Jorge, Eder, Matthias, Niederwieser, Dietger, Mohty, Mohamad, Nagler, Arnon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100212/
https://www.ncbi.nlm.nih.gov/pubmed/27821187
http://dx.doi.org/10.1186/s13045-016-0347-1
_version_ 1782466094790868992
author Shimoni, Avichai
Labopin, Myriam
Savani, Bipin
Volin, Liisa
Ehninger, Gerhard
Kuball, Jurgen
Bunjes, Donald
Schaap, Nicolaas
Vigouroux, Stephane
Bacigalupo, Andrea
Veelken, Hendrik
Sierra, Jorge
Eder, Matthias
Niederwieser, Dietger
Mohty, Mohamad
Nagler, Arnon
author_facet Shimoni, Avichai
Labopin, Myriam
Savani, Bipin
Volin, Liisa
Ehninger, Gerhard
Kuball, Jurgen
Bunjes, Donald
Schaap, Nicolaas
Vigouroux, Stephane
Bacigalupo, Andrea
Veelken, Hendrik
Sierra, Jorge
Eder, Matthias
Niederwieser, Dietger
Mohty, Mohamad
Nagler, Arnon
author_sort Shimoni, Avichai
collection PubMed
description BACKGROUND: Myeloablative (MAC) and reduced-intensity conditioning (RIC) are established approaches for allogeneic stem cell transplantation (SCT) in acute myeloid leukemia (AML). Most deaths after MAC occur within the first 2 years after SCT, while patients surviving leukemia-free for 2 years can expect a favorable long-term outcome. However, there is paucity of data on the long-term outcome (beyond 10 years) and the pattern of late events following RIC due to the relative recent introduction of this approach. METHODS: We analyzed long-term outcomes in a cohort of 1423 AML patients, age ≥50 years, after SCT from HLA-matched siblings, during the years 1997–2005, median follow-up 8.3 years (0.1–17). RESULTS: The 10-year leukemia-free survival (LFS) was 31 % (95CI, 27–35) and 32 % (28–35) after MAC and RIC, respectively (P = 0.57). The 10-year GVHD/ relapse-free survival (GRFS), a surrogate for quality of life was 22 % (18–25) and 21 % (18–24), respectively (P = 0.79). The 10-year non-relapse mortality (NRM) was higher and relapse rate was lower after MAC, throughout the early and late post-transplant course. The 10-year LFS among 584 patients surviving leukemia-free 2 years after SCT was 71 % (65–76) and 73 % (67–78) after MAC and RIC, respectively (P = 0.76). Advanced leukemia at SCT was the major predictor of LFS subsequent to the 2-year landmark. Relapse was the major cause of late death after both regimens; however, NRM and in particular chronic graft-versus-host disease and second cancers were more common causes of late death after MAC. CONCLUSIONS: Long-term LFS and GRFS are similar after RIC and MAC. Most events after RIC or MAC occur within the first 2 years after SCT. Patients who are leukemia-free 2 years after SCT can expect similar good subsequent outcome after both approaches. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-016-0347-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5100212
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51002122016-11-08 Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation Shimoni, Avichai Labopin, Myriam Savani, Bipin Volin, Liisa Ehninger, Gerhard Kuball, Jurgen Bunjes, Donald Schaap, Nicolaas Vigouroux, Stephane Bacigalupo, Andrea Veelken, Hendrik Sierra, Jorge Eder, Matthias Niederwieser, Dietger Mohty, Mohamad Nagler, Arnon J Hematol Oncol Research BACKGROUND: Myeloablative (MAC) and reduced-intensity conditioning (RIC) are established approaches for allogeneic stem cell transplantation (SCT) in acute myeloid leukemia (AML). Most deaths after MAC occur within the first 2 years after SCT, while patients surviving leukemia-free for 2 years can expect a favorable long-term outcome. However, there is paucity of data on the long-term outcome (beyond 10 years) and the pattern of late events following RIC due to the relative recent introduction of this approach. METHODS: We analyzed long-term outcomes in a cohort of 1423 AML patients, age ≥50 years, after SCT from HLA-matched siblings, during the years 1997–2005, median follow-up 8.3 years (0.1–17). RESULTS: The 10-year leukemia-free survival (LFS) was 31 % (95CI, 27–35) and 32 % (28–35) after MAC and RIC, respectively (P = 0.57). The 10-year GVHD/ relapse-free survival (GRFS), a surrogate for quality of life was 22 % (18–25) and 21 % (18–24), respectively (P = 0.79). The 10-year non-relapse mortality (NRM) was higher and relapse rate was lower after MAC, throughout the early and late post-transplant course. The 10-year LFS among 584 patients surviving leukemia-free 2 years after SCT was 71 % (65–76) and 73 % (67–78) after MAC and RIC, respectively (P = 0.76). Advanced leukemia at SCT was the major predictor of LFS subsequent to the 2-year landmark. Relapse was the major cause of late death after both regimens; however, NRM and in particular chronic graft-versus-host disease and second cancers were more common causes of late death after MAC. CONCLUSIONS: Long-term LFS and GRFS are similar after RIC and MAC. Most events after RIC or MAC occur within the first 2 years after SCT. Patients who are leukemia-free 2 years after SCT can expect similar good subsequent outcome after both approaches. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-016-0347-1) contains supplementary material, which is available to authorized users. BioMed Central 2016-11-08 /pmc/articles/PMC5100212/ /pubmed/27821187 http://dx.doi.org/10.1186/s13045-016-0347-1 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Shimoni, Avichai
Labopin, Myriam
Savani, Bipin
Volin, Liisa
Ehninger, Gerhard
Kuball, Jurgen
Bunjes, Donald
Schaap, Nicolaas
Vigouroux, Stephane
Bacigalupo, Andrea
Veelken, Hendrik
Sierra, Jorge
Eder, Matthias
Niederwieser, Dietger
Mohty, Mohamad
Nagler, Arnon
Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation
title Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation
title_full Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation
title_fullStr Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation
title_full_unstemmed Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation
title_short Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation
title_sort long-term survival and late events after allogeneic stem cell transplantation from hla-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of european group for blood and marrow transplantation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100212/
https://www.ncbi.nlm.nih.gov/pubmed/27821187
http://dx.doi.org/10.1186/s13045-016-0347-1
work_keys_str_mv AT shimoniavichai longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta
AT labopinmyriam longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta
AT savanibipin longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta
AT volinliisa longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta
AT ehningergerhard longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta
AT kuballjurgen longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta
AT bunjesdonald longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta
AT schaapnicolaas longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta
AT vigourouxstephane longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta
AT bacigalupoandrea longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta
AT veelkenhendrik longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta
AT sierrajorge longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta
AT edermatthias longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta
AT niederwieserdietger longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta
AT mohtymohamad longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta
AT naglerarnon longtermsurvivalandlateeventsafterallogeneicstemcelltransplantationfromhlamatchedsiblingsforacutemyeloidleukemiawithmyeloablativecomparedtoreducedintensityconditioningareportonbehalfoftheacuteleukemiaworkingpartyofeuropeangroupforbloodandmarrowtransplanta